RT期刊文章SR电子T1先前的残疾影响复苏和甲基强的松龙治疗的多发性硬化复发吗?乔(P4.189)摩根富首页林明神经学神经病学FD Lippincott Williams &威尔金斯SP P4.189 VO 82是10补充A1克里斯蒂娜•雷默A1拉娅Grau-Lopez A1玛丽亚Tintore-Subirana A1亚历克斯·罗维拉A1 Lluis Ramio A1 Luis Brieva A1艾伯特Saiz A1卡洛斯号A1安东尼奥诺A1奥尔加·卡A1弗兰托雷斯A1何塞韦森特Hervas A1 Xavier好吃的A1琼哥年2014 UL //www.ez-admanager.com/content/82/10_Supplement/P4.189.abstract AB目的:评估pre-relapse残疾和女士复发之间的关系严重程度和恢复后甲基强的松龙(MP)。分析之间的关系钆增强病变MRI (Gd +)和复发的严重性。背景:神经功能障碍发生在多发性硬化症(MS)复发。很少有研究分析复苏后复发女士之前根据残疾。设计/方法:49 48 MS患者的复发记录在第四阶段,多中心、随机、双盲试验证实口服不次于静脉议员在减少eds、女士和MRI病灶复发。复发与eds评估。强度基于eds障碍≤或> 1.0。恢复评估通过比例的患者改善蠅1点在eds 1, 4, 12周post-MP。Gd +病变以基线。 Relapse intensity and degree of recovery compared between patients with EDSS 蠅 or <3.0 before relapse. Relationships between relapse intensity and recovery were analyzed. RESULTS: Mean age: 39±7.8 years. Median EDSS before relapse 2.0 (1.5-3); median EDSS at relapse 3.5 (2.5-4). EDSS impairment of 1.0 in 29 patients, 1.5-2.5 in 18, and 蠅3.0 in 2. Patients with no improvement: 54% at week 1, 32% at week 4, and 27% at week 12. Patients with EDSS 蠅3.0 (n=20) before relapse had more severe relapses than those with EDSS <3.0 (n=28) (83.3% vs. 51.4%; p=0.04). Improvement was smaller in patients with EDSS 蠅3.0 before relapse (18.2%, 45.5%, 54.5% at 1, 4, 12 weeks, respectively, vs. 47.2%, 66.7%, 75%; p=0.05). Relapse intensity was not related to improvement at 1, 4, 12 weeks (p=0.416). Number of Gd+ lesions was not associated with relapse intensity at time of relapse, before MP treatment (EDSS>1: 3.65±6.9 vs EDSS<1: 2.7±4.3, p=0.29). CONCLUSIONS: Patients with greater disability had more severe relapses and smaller improvements after MP. Relapse severity did not affect improvement and was not related to number of Gd+ lesions at relapse. Study Supported by:Disclosure: Dr. Ramo has received research support from Biogen Idec. Dr. Grau-Lopez has nothing to disclose. Dr. Tintore-Subirana has received personal compensation for activities with Bayer Schering, Merck Serono, Biogen Idec, Teva Neuroscience, Sanofi-Aventis Pharmaceuticals Inc., and Novartis as a consultant and/or speaker. Dr. Rovira has received personal compensation for activities with Bayer Schering, Sanofi-Aventis Pharmaceuticals Inc., Bracco, Merck Serono, Teva Neurosciences, Novartis, and Biogen Idec. Dr. Rovira has received personal compensation in an editorial capacity for the American Journal of Neuroradiology, and Neuroradiology. Dr. Rovira has received research support from Bayer Schering. Dr. Girona has received personal compensation for activities with Biogen Idec, Merck Serono, Bayer-Schering, Teva Neuroscience, Sanofi-Aventis Pharmaceuticals Inc., and Almirall. Dr. Brieva has nothing to disclose. Dr. Saiz has received personal compensation for activities with Bayer Schering, Merck Serono, Biogen Idec, Sanofi-Aventis Pharmaceuticals Inc., Teva Neuroscience, and Novartis. Dr. Nos has nothing to disclose. Dr. Cano has nothing to disclose. Dr. Torres has nothing to disclose. Dr. Torres has nothing to disclose. Dr. Hervas has nothing to disclose. Dr. Montalban has received personal compensation for activities with Bayer Pharmaceuticals Corp., BIogen Idec, EMD Serono, and Genente. Dr. Costa has nothing to disclose.Wednesday, April 30 2014, 7:30 am-11:00 am